Single GLP-1 agonism against dual GIP/GLP-1 activity, and what that difference means when selecting a metabolic reference compound.
At a glance
- Semaglutide: single-receptor agonist acting at the GLP-1 receptor.
- Tirzepatide: dual agonist acting at both the GIP and GLP-1 receptors.
- The difference is receptor coverage, not potency at one shared target.
- Both are acylated for extended duration and supplied lyophilised at ≥99% HPLC purity.
Receptor profile
Semaglutide is a GLP-1 analogue: the backbone follows human GLP-1 with substitutions that resist enzymatic degradation, plus a fatty-acid chain that promotes albumin binding and a longer presence in model systems. Its pharmacology in published work is effectively a single-axis story — what happens when the GLP-1 receptor is engaged for a prolonged period.
Tirzepatide is built on the GIP sequence rather than the GLP-1 sequence, and is engineered to activate both receptors from one molecule. The literature describes its GIP and GLP-1 activities as unbalanced rather than equal, which is a recurring point in receptor pharmacology papers and matters when interpreting results.
What that means experimentally
- Isolating GLP-1 receptor effects: semaglutide is the cleaner reference compound.
- Studying incretin co-signalling or additive receptor effects: tirzepatide introduces a second axis in a single treatment.
- Receptor-knockout or antagonist designs: tirzepatide requires controls for both receptors, semaglutide for one.
- Comparative curves: differences in reported response are frequently attributable to receptor coverage rather than raw affinity, and should be reported that way.
Handling in the laboratory
Both are supplied as lyophilised powder, stored sealed at -20°C and protected from light. Both are reconstituted slowly with bacteriostatic or sterile water, swirled rather than shaken, and kept refrigerated once in solution.
Acylated peptides of this class are sensitive to freeze-thaw cycling. Where a study runs over several sessions, prepare single-use aliquots at the point of reconstitution rather than returning repeatedly to one vial.
Choosing a comparator
Most metabolic study designs include semaglutide as the established single-agonist reference and add tirzepatide when the question concerns dual incretin activity. Where a triple-agonist arm is also planned, tirzepatide is the conventional mid-point between semaglutide and retatrutide.
These compounds are supplied strictly as laboratory reference materials. Nothing here describes use in humans or animals, and no dosing information is provided.